keyword
MENU ▼
Read by QxMD icon Read
search

Gemcitabine toxicity

keyword
https://www.readbyqxmd.com/read/28230029/clinical-efficacy-and-safety-of-gemcitabine-plus-nedaplatin-in-the-treatment-of-advanced-nasopharyngeal-carcinoma
#1
Yan Hu, Jiang Tao Fu, Dongmei Shi, Biao Feng, Zhichao Shi
OBJECTIVE: The purpose was to explore the clinical effects and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma. MATERIALS AND METHODS: From March 2014 to August 2015, we recruited 63 advanced nasopharyngeal carcinoma patients in our hospital. Moreover, the 62 cases were randomly divided into control group (n = 31) and treatment group (n = 32). Patients in the control groups were treated with 5-fluorouracil 500 mg/m 2 + 500 ml 0...
December 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28225482/a-case-report-of-posterior-reversible-encephalopathy-syndrome-in-a-patient-receiving-gemcitabine-and-cisplatin
#2
Hannah Cherniawsky, Neesha Merchant, Micheal Sawyer, Maria Ho
RATIONALE: Posterior reversible encephalopathy syndrome (PRES) is a subacute syndrome causing characteristic neurologic and radiologic findings. PRES is predominantly caused by malignant hypertension though it has been associated with immunosuppressive treatments such as chemotherapy. PATIENT CONCERNS: We describe a case of a 58 year old female who developed fluctuant level of consciousness, agitation. DIAGNOSIS: MRI findings were in keeping with posterior reversible encephalopathy syndrome following cycle 6 of palliative gemcitabine and cisplatin therapy for metastatic cholangiocarcinoma...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28224231/nc-6004-phase-i-study-in-combination-with-gemcitabine-for-advanced-solid-tumors-and-population-pk-pd-analysis
#3
Toshihiko Doi, Tetsuya Hamaguchi, Kohei Shitara, Satoru Iwasa, Yasuhiro Shimada, Mitsunori Harada, Kenichiro Naito, Naoto Hayashi, Atsuhiro Masada, Atsushi Ohtsu
OBJECTIVES: This study was an open-label phase I study to confirm the safety and tolerability of NC-6004 in combination with gemcitabine in Japanese patients with advanced solid tumors and to assess the PK effects of NC-6004 monotherapy. METHODS: This phase I study used a 3 + 3 design to determine the maximum tolerated dose (MTD) and recommended dose of NC-6004 combined with gemcitabine. Safety and pharmacokinetics were assessed. The administration of NC-6004 alone was started at 60 mg/m(2) every treatment cycle (21 days per cycle)...
February 21, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28222309/gemcitabine-erlotinib-versus-gemcitabine-erlotinib-capecitabine-in-the-first-line-treatment-of-patients-with-metastatic-pancreatic-cancer-efficacy-and-safety-results-of-a-phase-iib-randomised-study-from-the-spanish-ttd-collaborative-group
#4
Antonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, Ruth Vera, Vega Iranzo, Inmaculada Ales, Sara Arévalo, Aleydis Pisa, Marta Martín, Antonieta Salud, Esther Falcó, Alberto Sáenz, José Luis Manzano Mozo, Gema Pulido, Joaquina Martínez Galán, Roberto Pazo-Cid, Fernando Rivera, Teresa García García, Olbia Serra, Eva Ma Fernández Parra, Alicia Hurtado, Ma José Gómez Reina, Luis Jesús López Gomez, Esther Martínez Ortega, Manuel Benavides, Enrique Aranda
BACKGROUND: Gemcitabine and erlotinib have shown a survival benefit in the first-line setting in metastatic pancreatic cancer (mPC). The aim of this study was to assess whether combining capecitabine (C) with gemcitabine + erlotinib (GE) was safe and effective versus GE in patients with mPC. PATIENTS AND METHODS: Previously untreated mPC patients were randomised to receive G (1000 mg/m(2), days 1, 8, 15) + E (100 mg/day, days 1-28) + C (1660 mg/m(2), days 1-21) or GE, q4 weeks, until progression or unacceptable toxicity...
February 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28221727/docetaxel-bevacizumab-and-gemcitabine-for-very-high-risk-sarcomas-in-adolescents-and-young-adults-a-single-center-experience
#5
Christopher Kuo, Paul M Kent, Antonio D Logan, Karen B Tamulonis, Kristen L Dalton, Marta Batus, Karen Fernandez, Rebecca E Mcfall
BACKGROUND: Adolescent and young adult (AYA) patients with very high risk sarcomas have poor outcomes and are in need of novel therapies. PROCEDURE: From January 2005 to February 2016, we retrospectively identified all AYA patients with relapsed or metastatic high-grade sarcomas, who were treated with at least one cycle of docetaxel (T), bevacizumab (A), and gemcitabine (G) (TAG ; T = 100 mg/m(2) Day 8, A = 15 mg/kg Day 1, G = 1,000 mg/m(2) Days 1 and 8). RESULTS: Fourteen patients, median age of 20 (15-30), received a total of 80 cycles of TAG, and were followed for a median of 83 months...
April 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28217315/gemcitabine-induced-cardiomyopathy-a-case-of-multiple-hit-cardiotoxicity
#6
Donya Mohebali, Jason Matos, James Ducksoon Chang
Gemcitabine is a commonly used antineoplastic agent used to treat a variety of cancers with rarely reported cardiac side effects. We describe a case of a 67-year-old woman with follicular lymphoma who experienced a rarely reported side effect of gemcitabine: cardiomyopathy. This case highlights a multiple hit mechanism of myocyte damage that may occur following the use of multiple cardio-toxic agents despite their administration in doses not associated with cardiotoxicity.
February 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28203300/a-modified-regimen-of-biweekly-gemcitabine-and-nab-paclitaxel-in-patients-with-metastatic-pancreatic-cancer-is-both-tolerable-and-effective-a-retrospective-analysis
#7
Daniel H Ahn, Kavya Krishna, Marlo Blazer, Joshua Reardon, Lai Wei, Christina Wu, Kristen K Ciombor, Anne M Noonan, Sameh Mikhail, Tanios Bekaii-Saab
BACKGROUND: Treatment with nab-paclitaxel with gemcitabine demonstrates a survival advantage when compared with single-agent gemcitabine. However, the combination is associated with significant toxicities, leading to a high rate of drug discontinuation. We implemented a modified regimen of gemcitabine and nab-paclitaxel (mGNabP) in an attempt to minimize toxicities while maintaining efficacy. METHODS: A total of 79 evaluable patients with metastatic pancreatic adenocarcinoma (mPC) treated with a modified regimen of gemcitabine (1000 mg/m(2)) and nab-paclitaxel (125 mg/m(2)) on days 1, 15 of every 28-day cycle were identified from our prospective database...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28196310/gemcitabine-cisplatin-versus-gemcitabine-oxaliplatin-doublet-chemotherapy-in-advanced-gallbladder-cancers-a-match-pair-analysis
#8
Anant Ramaswamy, Vikas Ostwal, Rakesh Pinniti, Sadhana Kannan, Prabhat Bhargava, Chaitali Nashikkar, Jimmy Mirani, Shripad Banavali
BACKGROUND: Gemcitabine-cisplatin (GC) and gemcitabine-oxaliplatin (GO) are the most commonly used regimens in advanced gallbladder cancer (GBC). METHODS: The data of patients with advanced GBC, treated between January 2013 and June 2015 were retrieved. A 1:1 matching without replacement was performed by using nearest neighbour matching method. RESULTS: 326 patients (163 GC and 163 GO), were matched 1:1 by age and gender. The response rates for GC and GO were 31...
February 14, 2017: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/28192597/a-phase-2-and-biomarker-study-of-cabozantinib-in-patients-with-advanced-cholangiocarcinoma
#9
Lipika Goyal, Hui Zheng, Matthew B Yurgelun, Thomas A Abrams, Jill N Allen, James M Cleary, Michelle Knowles, Eileen Regan, Amanda Reardon, Anna Khachatryan, Rakesh K Jain, Valentina Nardi, Darrell R Borger, Dan G Duda, Andrew X Zhu
BACKGROUND: Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond first-line gemcitabine/platinum-based chemotherapy. A single-arm, phase 2 and biomarker study of cabozantinib, a multikinase inhibitor with potent activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET, was performed for patients with advanced refractory cholangiocarcinoma. METHODS: Previously treated patients with unresectable or metastatic cholangiocarcinoma received cabozantinib (60 mg orally and daily on a continuous schedule)...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/28192388/degradable-starch-microspheres-transcatheter-arterial-chemoembolization-dsm-tace-in-intrahepatic-cholangiocellular-carcinoma-icc-results-from-a-national-multi-center-study-on-safety-and-efficacy
#10
Andreas Schicho, Philippe L Pereira, Manfred Pützler, Katharina Michalik, Thomas Albrecht, Claus Nolte-Ernsting, Christian Stroszczynski, Philipp Wiggermann
BACKGROUND The aim of this study was to evaluate the safety and efficacy of DSM (degradable starch microspheres) as an embolic agent in transarterial chemoembolization in the treatment of intrahepatic cholangiocellular carcinoma (ICC). MATERIAL AND METHODS This was a national, multi-center observational cohort study on the safety and efficacy of DSM-TACE using mitomycin, gemcitabine, cisplatin, doxorubicin, and carboplatin in palliative treatment of ICC. Recruitment period for the study was from January 2010 to June 2014...
February 13, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28186974/a-notch-sensitive-upar-regulated-oncolytic-adenovirus-effectively-suppresses-pancreatic-tumor-growth-and-triggers-synergistic-anticancer-effects-with-gemcitabine-and-nab-paclitaxel
#11
Ana Mato-Berciano, Giulia Raimondi, Maria Victoria Maliandi, Ramon Alemany, Lluis Montoliu, Cristina Fillat
Notch signaling pathway is an embryonic program that becomes reactivated in pancreatic cancer and contributes to cancer stem cell (CSC) maintenance. We explored the concept of oncolytic adenoviral activity in response to Notch activation signaling, in the context of a chimeric promoter with uPAR regulatory sequences, as a strategy to drive its activity in neoplastic and CSC. We explored the advantages of a chemo-virotherapy approach based on synergistic combinations. Regulatory sequences recognized by the transcriptional factor CSL upstream a minimal uPAR promoter were engineered in adenoviral vectors and in the oncolytic adenovirus AdNuPARmE1A...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28181940/stable-disease-in-a-patient-with-metastatic-leiomyosarcoma-treated-with-trabectedin
#12
Ketty Tavella, Alessandro Villanucci, Laura Vannini, Daniele Lavacchi, Silvia Montelatici, Gianni Amunni, Teresita Mazzei
Leiomyosarcomas represent the most common variant of uterine sarcomas, and are also considered to be the least chemosensitive. To date, adriamycin and ifosfamide are believed to be the most effective drugs for its treatment, in addition to docetaxel and gemcitabine. Recently, the introduction of trabectedin has provided clinicians with another treatment option, and the drug may have some benefits for patients as it may allow for long-term treatment. We present the case of a patient who previously failed multiple cycles of chemotherapy and who was subsequently treated with 30 cycles of trabectedin as third-line therapy for multiple metastases of uterine leiomyosarcoma...
February 8, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28179351/a-multicenter-phase-ii-study-of-gemcitabine-plus-s-1-chemotherapy-for-advanced-biliary-tract-cancer
#13
Shiho Arima, Kyoko Shimizu, Tomoyoshi Okamoto, Masao Toki, Yutaka Suzuki, Naohiro Okano, Daisuke Naruge, Kirio Kawai, Takaaki Kobayashi, Akiyoshi Kasuga, Hiroshi Kitamura, Atuko Takasu, Fumio Nagashima, Masanori Sugiyama, Junji Furuse
BACKGROUND: Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC). A phase II trial has also suggested promising activity of GEM plus S-1 chemotherapy against advanced BTC. The aim of this study was to evaluate the efficacy and safety of GEM plus S-1 chemotherapy in patients with advanced BTC. PATIENTS AND METHODS: The eligibility criteria were as follows: histologically-proven BTC, unresectable or recurrent disease, ECOG performance status (PS) 0-1 regardless of previous treatment...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28179342/phase-i-study-of-nab-paclitaxel-plus-gemcitabine-as-neoadjuvant-therapy-for-borderline-resectable-pancreatic-cancer
#14
Ken-Ichi Okada, Seiko Hirono, Manabu Kawai, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Masaki Ueno, Shinya Hayami, Hiroki Yamaue
BACKGROUND/AIM: The aim of this study was to investigate the safety and feasibility of neoadjuvant nab-paclitaxel plus gemcitabine therapy for patients with borderline resectable pancreatic carcinoma (BRPC). PATIENTS AND METHODS: The study was a prospective single-center phase I trial for patients with BRPC. The primary endpoint was the toxicity, and secondary endpoints were the resection rate, the R0 resection rate and quality of life (QOL) regarding the peripheral sensory neuropathy (PSN)...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28176634/targeting-the-akt-pi3k-signaling-pathway-as-a-potential-therapeutic-strategy-for-the-treatment-of-pancreatic-cancer
#15
Safieh Ebrahimi, Mina Hosseini, Soodabeh Shahidsales, Mina Maftouh, Gordon A Ferns, Majid Ghayour-Mobarhan, Seyed Mahdi Hassanian, Amir Avan
The phosphoinositide 3 kinase AKT mammalian target of rapamycin (PI3K-AKT-mTOR) signaling pathway is an important signaling pathway in pancreatic cancer (PC). It is frequently activated in PC and is associated with worse outcome. Aberrant activation of this pathway is involved in cell metabolism and survival, cell cycle progression, regulation of apoptosis, protein synthesis, and genomic instability. Several agents have been developed to target Akt/PI3K pathways, including PI3K inhibitors, (e.g. LY294002, Wortmannin), PI3K/mTOR inhibitors (e...
February 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28167569/use-of-systemic-therapy-concurrent-with-cranial-radiotherapy-for-cerebral-metastases-of-solid-tumors
#16
Maikel Verduin, Jaap D Zindler, Hanneke M A Martinussen, Rob L H Jansen, Sander Croes, Lizza E L Hendriks, Danielle B P Eekers, Ann Hoeben
: The incidence of brain metastases of solid tumors is increasing. Local treatment of brain metastases is generally straightforward: cranial radiotherapy (e.g., whole-brain radiotherapy or stereotactic radiosurgery) or resection when feasible. However, treatment becomes more complex when brain metastases occur while other metastases, outside of the central nervous system, are being controlled with systemic therapy (chemotherapeutics, molecular targeted agents, or monoclonal antibodies)...
February 6, 2017: Oncologist
https://www.readbyqxmd.com/read/28152544/exosomes-confer-chemoresistance-to-pancreatic-cancer-cells-by-promoting-ros-detoxification-and-mir-155-mediated-suppression-of-key-gemcitabine-metabolising-enzyme-dck
#17
Girijesh Kumar Patel, Mohammad Aslam Khan, Arun Bhardwaj, Sanjeev K Srivastava, Haseeb Zubair, Mary C Patton, Seema Singh, Moh'd Khushman, Ajay P Singh
BACKGROUND: Chemoresistance is a significant clinical problem in pancreatic cancer (PC) and underlying molecular mechanisms still remain to be completely understood. Here we report a novel exosome-mediated mechanism of drug-induced acquired chemoresistance in PC cells. METHODS: Differential ultracentrifugation was performed to isolate extracellular vesicles (EVs) based on their size from vehicle- or gemcitabine-treated PC cells. Extracellular vesicles size and subtypes were determined by dynamic light scattering and marker profiling, respectively...
February 2, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28144095/oxaliplatin-related-neuropathy-in-indian-patients-no-difference-between-generic-and-original-molecules
#18
Bhawna Sirohi, Vikas Ostwal, Shaheenah Dawood, Gilberto Lopes, Sanjay Talole, Chaitali Nashikkar, Shailesh Shrikhande
BACKGROUND: Oxaliplatin-induced neuropathy is a dose-limiting toxicity that significantly affects patients' quality of life. The aim of this study was to compare its occurrence between a generic versus the original molecule in Indian patients. MATERIALS AND METHODS: Between August 2012 and July 2013, 163 patients receiving oxaliplatin were prospectively enrolled. A data recording form was used in the clinic to record detailed information. RESULTS: The median age of patients was 55 years (range, 19-79)...
October 2016: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28142123/plasmonic-nanocarrier-grid-enhanced-raman-sensor-for-studies-of-anticancer-drug-delivery
#19
Katarzyna Kurzątkowska, Ty Santiago, Maria Hepel
Targeted drug delivery systems using nanoparticle nanocarriers offer remarkable promise for cancer therapy by discriminating against devastating cytotoxicity of chemotherapeutic drugs to healthy cells. To aid in the development of new drug nanocarriers, we propose a novel plasmonic nanocarrier grid-enhanced Raman sensor which can be applied for studies and testing of drug loading onto the nanocarriers, attachment of targeting ligands, dynamics of drug release, assessment of nanocarrier stability in biological environment, and general capabilities of the nanocarrier...
May 15, 2017: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/28133097/-a-study-of-gemctabine-plus-nab-paclitaxel-therapy-for-advanced-local-progressive-pancreatic-cancer
#20
Yutaka Itoh, Hiroyuki Saito, Shunsuke Yamagishi, Yuki Suematsu, Miyuki Takahashi, Mao Nakayama, Michiko Fukabori, Akihiko Morita, Kazuhiko Wakabayashi
We studied the significance of gemcitabine plus nab-paclitaxel(GnP)therapy for locally progressive pancreatic cancer. We enrolled 10 patients with local progression without distant metastasis. We used GnP therapy for the ablative borderline resectable(BR)and unresectable(UR)cases based on images that followed NCCN pancreatic cancer treatment guidelines. In 1 case of resectable(R)pancreatic cancer, the tumor was located in the pancreas body but we determined that surgery was impossible because of the underlying disease detected on imaging analysis...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
103368
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"